The Use of Positron Emission Tomography in Soft Tissue Sarcoma Patients under Therapy with Trabectedin

The Use of Positron Emission Tomography in Soft Tissue Sarcoma Patients under Therapy with Trabectedin

Background: We used 2-deoxy-2-[18F] fluoro-D-glucose (FDG) positron emission tomography (PET) to evaluate the FDG uptake in patients with advanced and/or metastatic soft tissue sarcoma (STS) undergoing therapy with Ecteinascidin-743 (ET-743, Trabectedin, YondelisTM). Patients and Methods: The pilot...

Full description

Bibliographic Details
Main Authors:	Gerlinde Egerer, Anthony D. Ho, Antonia Dimitrakopoulou-Strauss, Thomas Schmitt, Patrick Wuchter, Bernd Kasper
Format:	Article
Language:	English
Published:	MDPI AG 2009-07-01
Series:	Marine Drugs
Subjects:	fluorodeoxyglucose positron emission tomography RECIST soft tissue sarcoma trabectedin
Online Access:	http://www.mdpi.com/1660-3397/7/3/331/

Similar Items

Radiosensitizing Effect of Trabectedin on Human Soft Tissue Sarcoma Cells
by: Mauro Loi, et al.
Published: (2022-11-01)

Trabectedin for Patients with Advanced Soft Tissue Sarcoma: A Non-Interventional, Retrospective, Multicenter Study of the Italian Sarcoma Group
by: Emanuela Palmerini, et al.
Published: (2021-03-01)

Combination of Trabectedin and Gemcitabine for Advanced Soft Tissue Sarcomas: Results of a Phase I Dose Escalating Trial of the German Interdisciplinary Sarcoma Group (GISG)
by: Bernd Kasper, et al.
Published: (2015-01-01)

Geriatric Assessment of Older Patients Receiving Trabectedin in First-Line Treatment for Advanced Soft Tissue Sarcomas: The E-TRAB Study from The German Interdisciplinary Sarcoma Group (GISG-13)
by: Bernd Kasper, et al.
Published: (2024-01-01)

Trabectedin for Patients with Advanced Soft Tissue Sarcoma: A Non-Interventional, Prospective, Multicenter, Phase IV Trial
by: Viktor Grünwald, et al.
Published: (2022-10-01)

Does the Use of Peripheral Immune-Related Markers Indicate Whether to Administer Pazopanib, Trabectedin, or Eribulin to Advanced Soft Tissue Sarcoma Patients?
by: Eijiro Shimada, et al.
Published: (2021-10-01)

Validation of Neutrophil Count as An Algorithm-Based Predictive Factor of Progression-Free Survival in Patients with Metastatic Soft Tissue Sarcomas Treated with Trabectedin
by: Alexandre de Nonneville, et al.
Published: (2019-03-01)

Trabectedin Plus Radiotherapy for Advanced Soft-Tissue Sarcoma: Experience in Forty Patients Treated at a Sarcoma Reference Center
by: Nadia Hindi, et al.
Published: (2020-12-01)

Impact of Pathological Stratification on the Clinical Outcomes of Advanced Well-Differentiated/Dedifferentiated Liposarcoma Treated with Trabectedin
by: Chiara Fabbroni, et al.
Published: (2021-03-01)

Trabectedin and Radiotherapy in Endometrial Stromal Sarcoma: A Case Report
by: Irene Carrasco García, et al.
Published: (2024-01-01)

Long-Time Progression-Free Survival with Trabectedin in Chemorefractory Metastatic Leiomyosarcoma of the Retroperitoneum: A Case Report
by: Andreas Reichinger
Published: (2023-09-01)

Pharmacometabolomics of trabectedin in metastatic soft tissue sarcoma patients
by: Giuseppe Corona, et al.
Published: (2023-08-01)

A Multicenter, Prospective, Observational Study to Assess the Clinical Activity and Impact on Symptom Burden and Patients’ Quality of Life in Patients with Advanced Soft Tissue Sarcomas Treated with Trabectedin in a Real-World Setting in Greece
by: Stefania Kokkali, et al.
Published: (2022-04-01)

<i>CUL4A</i>, <i>ERCC5</i>, and <i>ERCC1</i> as Predictive Factors for Trabectedin Efficacy in Advanced Soft Tissue Sarcomas (STS): A Spanish Group for Sarcoma Research (GEIS) Study
by: David S. Moura, et al.
Published: (2020-04-01)

A Growth Modulation Index-Based GEISTRA Score as a New Prognostic Tool for Trabectedin Efficacy in Patients with Advanced Soft Tissue Sarcomas: A Spanish Group for Sarcoma Research (GEIS) Retrospective Study
by: Javier Martínez-Trufero, et al.
Published: (2021-02-01)

Trabectedin Cardiotoxicity in Soft Tissue Sarcoma: A Case Series and Clinical Insights
by: David G. Gent, et al.
Published: (2022-11-01)

Trabectedin and lurbinectedin: Mechanisms of action, clinical impact, and future perspectives in uterine and soft tissue sarcoma, ovarian carcinoma, and endometrial carcinoma
by: Angiolo Gadducci, et al.
Published: (2022-11-01)

A Clear Cell Sarcoma Case: A Diagnostic and Treatment Challenge, with a Promising Response to Trabectedin
by: Mar Galera, et al.
Published: (2023-12-01)

Activity of TNT: a phase 2 study using talimogene laherparepvec, nivolumab and trabectedin for previously treated patients with advanced sarcomas (NCT# 03886311)
by: Sant P. Chawla, et al.
Published: (2023-05-01)

Immunologic Gene Signature Analysis Correlates Myeloid Cells and M2 Macrophages with Time to Trabectedin Failure in Sarcoma Patients
by: Brett A. Schroeder, et al.
Published: (2022-03-01)

PARP1 Inhibitor and Trabectedin Combination Does Not Increase Tumor Mutational Burden in Advanced Sarcomas—A Preclinical and Translational Study
by: Ymera Pignochino, et al.
Published: (2021-12-01)

Case Report of Suspected Rhabdomyolysis during Treatment with Trabectedin in a Patient with Metastatic Leiomyosarcoma
by: W. Lamm, et al.
Published: (2010-12-01)

Hepatic Positron Emission Tomography: Applications in Metabolism, Haemodynamics and Cancer
by: Miikka-Juhani Honka, et al.
Published: (2022-04-01)

Innovative Breakthroughs for the Treatment of Advanced and Metastatic Synovial Sarcoma
by: Lorena Landuzzi, et al.
Published: (2023-07-01)

Novel Insights into the Immunotherapy of Soft Tissue Sarcomas: Do We Need a Change of Perspective?
by: Andrej Ozaniak, et al.
Published: (2021-08-01)

Quantification of standardised uptake value for ¹⁸F-FDG positron emission tomography in Malaysia
by: Hanafi, Muhammad Hafiz
Published: (2017)

Trabectedin in Advanced High-Grade Uterine Leiomyosarcoma: A Case Report Illustrating the Value of18FDG-PET-CT in Assessing Treatment Response
by: M.J. Payne, et al.
Published: (2014-02-01)

Immunometabolic actions of trabectedin and lurbinectedin on human macrophages: relevance for their anti-tumor activity
by: Adrián Povo-Retana, et al.
Published: (2023-08-01)

Trabectedin and Plitidepsin: Drugs from the Sea that Strike the Tumor Microenvironment
by: Carlos M. Galmarini, et al.
Published: (2014-01-01)

Molecular Imaging of Aortic Valve Stenosis with Positron Emission Tomography
by: Reindert F. Oostveen, et al.
Published: (2022-06-01)

Soft tissue sarcomas: Evaluation by immunohistochemistry
by: Ibtisam Hussein Al Obaidi
Published: (2020-06-01)

Pharmacogenetic Study of Trabectedin-Induced Severe Hepatotoxicity in Patients with Advanced Soft Tissue Sarcoma
by: Maud Maillard, et al.
Published: (2020-12-01)

SOFT TISSUE SARCOMA: A MODERN VIEW TO THE PROBLEM
by: V.V. BENBERIN, et al.
Published: (2019-06-01)

Positron Emission Tomography in Merkel Cell Carcinoma
by: Christos Sachpekidis, et al.
Published: (2020-10-01)

Long-Term Response after 94 Cycles of Trabectedin in a Patient with Metastatic Leiomyosarcoma of the Lower Extremity
by: Magda Cordeiro, et al.
Published: (2020-02-01)

Integration of Serum Metabolomics into Clinical Assessment to Improve Outcome Prediction of Metastatic Soft Tissue Sarcoma Patients Treated with Trabectedin
by: Gianmaria Miolo, et al.
Published: (2020-07-01)

In-Silico Identification of Novel Pharmacological Synergisms: The Trabectedin Case
by: Laura Mannarino, et al.
Published: (2024-02-01)

Disposal of Radioactive Waste Generated at the End of 18F- Fluorodeoxyglucose Production for Positron Emission Tomography - Computed Tomography (PET-CT) Scan at Armed Forces Institute of Radiology and Imaging, Rawalpindi
by: Rizwan Bilal, et al.
Published: (2022-11-01)

Yield of FDG PET/CT for Defining the Extent of Disease in Patients with Kaposi Sarcoma
by: Louise Pesqué, et al.
Published: (2022-04-01)

Effect of the Combination of Trabectedin and Pegylated Liposomal Doxorubicin in a BRCA2 Mutation Carrier with Recurrent Platinum-Sensitive Ovarian Cancer
by: María Jesús Rubio Pérez
Published: (2017-05-01)